Longitudinal decline in striatal DAT binding in LRRK2 Parkinson’s disease: connections with CSF α-Synuclein Seeding Activity
Authors:
Preprint
Abstract
Objective: Parkinson’s disease (PD) associated with mutations in the LRRK2 gene exhibits considerable pathological heterogeneity and may not present with Lewy body pathology. The α-Syn seed amplification assay (SAA) performed on cerebrospinal fluid (CSF) has emerged as a reliable in vivo biomarker of α-Syn aggregation. In this study, we aim to investigate the longitudinal trajectories of striatal dopaminergic imaging in LRRK2 PD patients stratified by CSF α-Syn SAA status. Methods: Data were obtained from the Parkinson’s Progression Markers Initiative. CSF α-Syn aggregation was assessed using SAA. Striatal DAT specific binding ratios (SBR) were quantified using [¹²³I] FP-CIT SPECT at baseline, year 2, and year 4. Results: At baseline, the α-Syn SAA-negative LRRK2 PD group exhibited higher DAT binding in the contralateral putamen and ipsilateral putamen compared to the SAA-positive group with comparable disease duration. Longitudinally, linear mixed-effects models demonstrated that the α-Syn SAA-negative LRRK2 PD maintained significantly higher DAT binding in both the contralateral and ipsilateral putamen over time. A significant group × time interaction was identified in the contralateral caudate, suggesting a slower rate of DAT loss in the α-Syn SAA-negative group. Sensitivity analyses restricted to participants with complete baseline and follow-up imaging data largely confirmed the main LMEM findings. Conclusions: The observed differences in striatal dopaminergic degeneration between LRRK2 PD patients with and without detectable CSF α-synuclein aggregates may reflect region-specific vulnerability to underlying pathological processes. Our findings support the utility of CSF α-Syn SAA status as both a diagnostic and prognostic biomarker in LRRK2 PD.Keywords
All Related Versions
- Published version: Journal of Neurology, 272 (9), 1.
This publication has 43 references indexed in Scilit:
- Dopamine Transporter Imaging as Objective Monitoring Biomarker in Parkinson's DiseaseAnnals of Neurology, 2025
- Brain and Cerebrospinal Fluid α‐Synuclein Real‐Time Quaking‐Induced Conversion Identifies Lewy Body Pathology in LRRK2‐PDMovement Disorders, 2022
- α‐synuclein RT‐QuIC in cerebrospinal fluid of LRRK2‐linked Parkinson's diseaseAnnals of Clinical and Translational Neurology, 2019
- Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's diseaseMovement Disorders, 2019
- The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohortAnnals of Clinical and Translational Neurology, 2018
- Movement disorder society criteria for clinically established early Parkinson's diseaseMovement Disorders, 2018
- Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literatureMovement Disorders, 2017
- Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal FluidJAMA Neurology, 2017
- Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathiesAnnals of Clinical and Translational Neurology, 2016
- Clinical Correlations With Lewy Body Pathology inLRRK2-Related Parkinson DiseaseJAMA Neurology, 2015